Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?

In biotech, companies aren’t shy about sharing detailed results when they bolster their case

Molly Ferguson/STAT

By Adam FeuersteinAug. 11, 2026

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.